Company Analysis
Sign in

Chemomab Therapeutics Ltd. (CMMB)

Nasdaq: CMMB · Pharmaceutical Preparations · Tel Aviv · filing with the SEC since 2011
Full chart Alerts Compare
Grade5.0
◀ Past 4.8● Present 4.5▶ Future 5.7
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$9.0M+35.5%
Earnings per share$0.02-53.8%
Operating cash flow-$11.1M+27.7%
Cash$7.6M+23.1%
Debtn/a
Shareholders’ equity$12.3M-8.9%
Shares, diluted510.2M+42.1%
Return on equity-72.9%
The recordfrom its filings
Filings in 202637
Newest filingNov 10 · SCHEDULE 13D
Annual reportMar 23, 2026
Quarterly reportMay 11, 2023
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Smaller reporting company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13D
Activist holder notice
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form DEFA14A
Extra proxy material
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form DEFM14A
Merger proxy statement
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton CMMB · research, not advice